Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Goetz

Showing results (271-280 of 397) with videos related to

Pageof 40
Sort By:
Cancer Research|April 1, 2010
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancerJames N Ingle, Aman U Buzdar, Daniel J Schaid, et al.
Breast Cancer Research and Treatment|April 14, 2021
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)Tufia C Haddad, Jun He, Ciara C O'Sullivan, et al.
Molecular Cancer|January 16, 2024
Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancerHeba Alkhatib, Jason Conage-Pough, Sangita Roy Chowdhury, et al.
Clinical Pharmacology and Therapeutics|February 1, 2018
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen TherapyMatthew P Goetz, Katrin Sangkuhl, Henk-Jan Guchelaar, et al.
Breast Cancer Research : BCR|June 23, 2025
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trialRoberto A Leon-Ferre, K Dimitroff, C Yau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2012
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8Matthew P Goetz, Vera J Suman, Tanya L Hoskin, et al.
Future Oncology (London, England)|October 12, 2021
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancerCiara C O'Sullivan, Karla V Ballman, Linda McCall, et al.
NPJ Breast Cancer|March 30, 2024
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancerRoberto A Leon-Ferre, Jodi M Carter, David Zahrieh, et al.
Breast Cancer Research : BCR|May 24, 2023
Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumorsXiaojia Tang, Kevin J Thompson, Krishna R Kalari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2011
Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trialsMatthew P Goetz, Daniel J Schaid, D Lawrence Wickerham, et al.
Pageof 40

Showing results (271-280 of 397) with videos related to

Sort By:
Pageof 40
Cancer Research|April 1, 2010
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancerJames N Ingle, Aman U Buzdar, Daniel J Schaid, et al.
Breast Cancer Research and Treatment|April 14, 2021
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)Tufia C Haddad, Jun He, Ciara C O'Sullivan, et al.
Molecular Cancer|January 16, 2024
Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancerHeba Alkhatib, Jason Conage-Pough, Sangita Roy Chowdhury, et al.
Clinical Pharmacology and Therapeutics|February 1, 2018
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen TherapyMatthew P Goetz, Katrin Sangkuhl, Henk-Jan Guchelaar, et al.
Breast Cancer Research : BCR|June 23, 2025
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trialRoberto A Leon-Ferre, K Dimitroff, C Yau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2012
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8Matthew P Goetz, Vera J Suman, Tanya L Hoskin, et al.
Future Oncology (London, England)|October 12, 2021
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancerCiara C O'Sullivan, Karla V Ballman, Linda McCall, et al.
NPJ Breast Cancer|March 30, 2024
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancerRoberto A Leon-Ferre, Jodi M Carter, David Zahrieh, et al.
Breast Cancer Research : BCR|May 24, 2023
Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumorsXiaojia Tang, Kevin J Thompson, Krishna R Kalari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2011
Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trialsMatthew P Goetz, Daniel J Schaid, D Lawrence Wickerham, et al.
Pageof 40